Pulmonary Endothelium in Thromboembolism

The Pulmonary Endothelium: Function in health and disease

Volumn , Issue , 2009, Pages 471-483

  Lang, Irene M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Abnormal thrombus formation and resolution in vascular disorders; Blood coagulation and hemostasis defense mechanisms against bleeding; Chronic thromboembolic pulmonary hypertension (CTEPH); Endothelium and coagulation; Lung endothelium in abnormal clot clearance and in situ thrombosis; Platelet and EC crosstalk in venous thrombosis; Pulmonary endothelium in thromboembolism; Serial analysis of gene expression in venous thrombi; Vascular remodeling process and thrombus resolution organization

Indexed keywords

EID: 84873639410     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470747490.ch29     Document Type: Chapter

References (96)

1. Lilienfeld, D.E., Chan, E., Ehland, J. et al. (1990) Mortality from pulmonary embolism in the United States: 1962 to 1984. Chest, 98 (5), 1067-72.
2. Anderson, F.A. Jr., Wheeler, H.B., Goldberg, R.J. et al. (1991) A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Archives of Internal Medicine, 151 (5), 933-38.
3. Paraskos, J.A., Adelstein, S.J., Smith, R.E. et al. (1973) Late prognosis of acute pulmonary embolism. The New England Journal of Medicine, 289 (2), 55-58.
4. Dalen, J.E. and Dexter, L. (1969) Pulmonary embolism. The Journal of the American Medical Association, 207 (8), 1505-7.
5. Murphy, M.L. and Bulloch, R.T. (1968) Factors influencing the restoration of blood flow following pulmonary embolization as determined by angiography and scanning. Circulation, 38 (6), 1116-26.
6. Wagenvoort, C.A. (1995) Pathology of pulmonary thromboembolism. Chest, 107 (Suppl 1), 10S-17S.
7. Lang, I.M., Moser, K.M., and Schleef, R.R. (1998) Elevated expression of urokinase-like plasminogen activator and plasminogen activator inhibitor type 1 during the vascular remodeling associated with pulmonary thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology, 18 (5), 808-15.
8. Modarai, B., Burnand, K.G., Sawyer, B. et al. (2005) Endothelial progenitor cells are recruited into resolving venous thrombi. Circulation, 111 (20), 2645-53.
9. Cushman, M. (2007) Epidemiology and risk factors for venous thrombosis. Seminars in Hematology, 44 (2), 62-69.
10. Nossent, A.Y., Eikenboom, J.C., and Bertina, R.M. (2007) Plasma coagulation factor levels in venous thrombosis. Seminars in Hematology, 44 (2), 77-84.
11. Cines, D.B., Pollak, E.S., Buck, C.A. et al. (1998) Endothelial cells in physiology and in the patho physiology of vascular disorders. Blood, 91 (10), 3527-61.
12. Bonderman, D., Jakowitsch, J., Redwan, B. et al. (2008) Role for staphylococci in misguided throm bus resolution of chronic thromboembolic pulmonary hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 28 (4), 678-84.
13. Barnathan, E.S., Kuo, A., Van der Keyl, H. et al. (1988) Tissue-type plasminogen activator binding to human endothelial cells. Evidence for two distinct binding sites. The Journal of Biological Chemistry, 263 (16), 7792-99.
14. Welling, T.H., Huber, T.S., Messina, L.M. et al. (1996) Tissue plasminogen activator increases canine endothelial cell proliferation rate through a plasmin-independent, receptor-mediated mechanism. The Journal of Surgical Research, 66 (1), 36-42.
15. Levin, E.G. and Santell, L. (1987) Association of a plasminogen activator inhibitor (PAI-1) with the growth substratum and membrane of human endothelial cells. The Journal of Cell Biology, 105 (6Pt 1), 2543-49.
16. Loskutoff, D.J., Sawdey, M., and Mimuro, J. (1989) Type 1 plasminogen activator inhibitor. Progress in Hemostasis and Thrombosis, 9, 87-115.
17. Sawdey, M.S. and Loskutoff, D.J. (1991) Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. The Journal of Clinical Investigation, 88 (4), 1346-53.
18. Bajzar, L., Morser, J., and Nesheim, M. (1996) TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. The Journal of Biological Chemistry, 271 (28), 16603-8.
19. Kinlay, S., Libby, P., and Ganz, P. (2001) Endothelial function and coronary artery disease. Current Opinion in Lipidology, 12 (4), 383-89.
20. Zhao, Y., Young, S.L., McIntosh, J.C. et al. (2000) Ontogeny and localization of TGF-beta type I receptor expression during lung development. American Journal of Physiology: Lung Cellular and Molecular Physiology, 278 (6), L1231-39.
21. Hartsfield, C.L., Alam, J., and Choi, A.M. (1999) Differential signaling pathways of HO-1 gene expression in pulmonary and systemic vascular cells. American Journal ofPhysiology: Lung Cellular and Molecular Physiology, 277 (6), L1133-41.
22. Wright, L., Tuder, R.M., Wang, J. et al. (1998) 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 157 (1), 219-29.
23. Giaid, A., Yanagisawa, M., Langleben, D. et al. (1993) Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. The New England Journal of Medicine, 328 (24), 1732-39.
24. Tuder, R.M., Cool, C.D., Geraci, M.W. et al. (1999) Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. American Journal of Respiratory and Critical Care Medicine, 159 (6), 1925-32.
25. Rosenhek, R., Korschineck, I., Gharehbaghi-Schnell, E. et al. (2003) Fibrinolytic balance of the arterial wall: pulmonary artery displays increased fibrinolytic potential compared with aorta. Laboratory Investigation, 83 (6), 871-76.
26. Todd, A.S. (1972) Endothelium and fibrinolysis. Atherosclerosis, 15 (2), 137-40.
27. Carmeliet, P., Mulligan, R.C., Collen, D. et al. (1994) Transgenic animals as tools for the study of fibrinolysis in vivo Physiological consequences of loss of plasminogen activator gene function in mice. Journal of Internal Medicine, 236 (4), 455-59.
28. Kawai, Y., Matsumoto, Y., Watanabe, K. et al. (1996) Hemodynamic forces modulate the effects of cytokines on fibrinolytic activity of endothelial cells. Blood, 87 (6), 2314-21.
29. Schwenke, D.C. (1997) Comparison of aorta and pulmonary artery: II. LDL transport and metabolism correlate with susceptibility to atherosclerosis. Circulation Research, 81 (3), 346-54.
30. Stein, P.D. and Evans, H. (1967) An autopsy study of leg vein thrombosis. Circulation, 35 (4), 671-81.
31. Samad, F., Schneiderman, J., and Loskutoff, D. (1997) Expression of fibrinolytic genes in tissues from human atherosclerotic aneurysms and from obese mice. Annals of the New York Academy of Sciences, 811, 350-58; discussion 358-360.
32. Pepper, M.S., Montesano, R., Mandriota, S.J. et al. (1996) Angiogenesis: a paradigm for balanced extracellular proteolysis during cell migration and morphogenesis. Enzyme and Protein, 49 (1-3), 138-62.
33. Fearns, C., Samad, F., and Loskutoff, D.J. (1995) Synthesis and localization of PAI-1 in the vessel wall, in Vascular Control of Hemostasis, (ed. V.W.M. van Hinsbergh), Harwood, Amsterdam, pp. 207-26.
34. Fujii, S., Hopkins, W.E., and Sobel, B.E. (1991) Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombolysis. Circulation, 83 (2), 645-51.
35. Sawdey, M., Podor, T.J., and Loskutoff, D.J. (1989) Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. The Journal of Biological Chemistry, 264 (18), 10396-401.
36. Sawa, H., Fujii, S., and Sobel, B.E. (1992) Augmented arterial wall expression of type-1 plasminogen activator inhibitor induced by thrombosis. Arteriosclerosis and Thrombosis, 12 (12), 1507-15.
37. Kadish, J.L., Butterfield, C.E., and Folkman, J. (1979) The effect of fibrin on cultured vascular endothelial cells. Tissue and Cell, 11 (1), 99-108.
38. Gertler, J.P., Perry, L., L'ltalien, G. et al. (1993) Ambient oxygen tension modulates endothelial fibrinolysis. Journal of Vascular Surgery, 18 (6), 939-45; discussion 945-936.
39. Hong, K.H., Yoo, S.A., Kang, S.S. et al. (2006) Hypoxia induces expression of connective tissue growth factor in scleroderma skin fibroblasts. Clinical and Experimental Immunology, 146 (2), 362-70.
40. Hong, K.H., Lee, Y.J., Lee, E. et al. (2008) Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension. Circulation, 118 (7), 722-30.
41. Moser, K.M., Auger, W.R., and Fedullo, P.F. (1990) Chronic major-vessel thromboembolic pulmonary hypertension. Circulation, 81 (6), 1735-43.
42. Lang, I.M. (2004) Chronic thromboembolic pulmonary hypertension-not so rare after all. The New England Journal of Medicine, 350 (22), 2236-38.
43. Tapson, V.F. and Humbert, M. (2006) Incidence and prevalence of chronic thromboembolic pulmonary hypertension: from acute to chronic pulmonary embolism. Proceedings of the American Thoracic Society, 3 (7), 564-67.
44. Menendez, R., Nauffal, D., and Cremades, M.J. (1998) Prognostic factors in restoration of pulmonary flow after submassive pulmonary embolism: a multiple regression analysis. The European Respiratory Journal, 11 (3), 560-64.
45. Ribeiro, A., Lindmarker, P., Johnsson, H. et al. (1999) Pulmonary embolism: one-year follow-up with echocardiography doppler and five-year survival analysis. Circulation, 99 (10), 1325-30.
46. Pengo, V., Lensing, A.W., Prins, M.H. et al. (2004) Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. The New England Journal of Medicine, 350 (22), 2257-64.
47. Fedullo, P.F., Auger, W.R., Kerr, K.M. et al. (2001) Chronic thromboembolic pulmonary hypertension. The New England Journal of Medicine, 345 (20), 1465-72.
48. Wolf, M., Boyer-Neumann, C., Parent, F. et al. (2000) Thrombotic risk factors in pulmonary hypertension. The European Respiratory Journal, 15 (2), 395-99.
49. Lang, I.M., Klepetko, W., and Pabinger, I. (1996) No increased prevalence of the factor V Leiden mutation in chronic major vessel thromboembolic pulmonary hypertension (CTEPH). Thrombosis and Haemostasis, 76 (3), 476-77.
50. Olman, M.A., Marsh, J.J., Lang, I.M. et al. (1992) Endogenous fibrinolytic system in chronic large-vessel thromboembolic pulmonary hypertension. Circulation, 86 (4), 1241-48.
51. Lang, I.M., Marsh, J.J., Olman, M.A. et al. (1994) Parallel analysis of tissue-type plasminogen activator and type 1 plasminogen activator inhibitor in plasma and endothelial cells derived from patients with chronic pulmonary thromboemboli. Circulation, 90 (2), 706-12.
52. Marsh, J.J., Konopka, R.G., Lang, I.M. et al. (1994) Suppression of thrombolysis in a canine model of pulmonary embolism. Circulation, 90 (6), 3091-97.
53. Egermayer, P. and Peacock, A.J. (2000) Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. The European Respiratory Journal, 15 (3), 440-48.
54. Lang, I.M., Marsh, J.J., Konopka, R.G. et al. (1993) Factors contributing to increased vascular fibrinolytic activity in mongrel dogs. Circulation, 87 (6), 1990-2000.
55. Moser, K.M. and Bloor, C.M. (1993) Pulmonary vascular lesions occurring in patients with chronic major vessel thromboembolic pulmonary hypertension. Chest, 103 (3), 685-92.
56. Lang, I.M., Marsh, J.J., Olman, M.A. et al. (1994) Expression of type 1 plasminogen activator in hibitor in chronic pulmonary thromboemboli. Circulation, 89 (6), 2715-21.
57. Kyrle, P.A., Minar, E., Hirschl, M. et al. (2000) High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. The New England Journal of Medicine, 343 (7), 457-62.
58. Bonderman, D., Turecek, P.L., Jakowitsch, J. et al. (2003) High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. Thrombosis and Haemostasis, 90 (3), 372-76.
59. Lang, I.M., Moser, K.M., and Schleef, R.R. (1996) Expression of Kunitz protease inhibitor-containing forms of amyloid beta-protein precursor within vascular thrombi. Circulation, 94 (11), 2728-34.
60. Beck, L. Jr. and D'Amore, P.A. (1997) Vascular development: cellular and molecular regulation. The FASEB Journal, 11 (5), 365-73.
61. Albelda, S.M., Muller, W.A., Buck, C.A. et al. (1991) Molecular and cellular properties of PECAM-1 (endoCAM/CD31): a novel vascular cell-cell adhesion molecule. The Journal of Cell Biology, 114 (5), 1059-68.
62. Risau, W. and Flamme, I. (1995) Vasculogenesis. Annual Review of Cell and Developmental Biology, 11, 73-91.
63. Deng, Z., Morse, J.H., Slager, S.L. et al. (2000) Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. American Journal of Human Genetics, 67 (3), 737-44.
64. Harrison, R.E., Flanagan, J.A., Sankelo, M. et al. (2003) Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemor-rhagic telangiectasia. Journal of Medical Genetics, 40 (12), 865-71.
65. Kim, D.H., Iijima, H., Goto, K. et al. (1996) Human apolipoprotein E receptor 2. A novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in brain. The Journal of Biological Chemistry, 271 (14), 8373-80.
66. Brown, S.D., Twells, R.C., Hey, P.J. et al. (1998) Isolation and characterization of LRP6, a novel member of the low density lipoprotein receptor gene family. Biochemical and Biophysical Research Communications, 248 (3), 879-88.
67. Glagov, S., Weisenberg, E., Zarins, C.K. et al. (1987) Compensatory enlargement of human atherosclerotic coronary arteries. The New England Journal of Medicine, 316 (22), 1371-75.
68. Garland, C.J., Plane, F., Kemp, B.K. et al. (1995) Endothelium-dependent hyperpolarization: a role in the control of vascular tone. Trends in Pharmacological Sciences, 16 (1), 23-30.
69. Stamler, J.S., Singel, D.J., and Loscalzo, J. (1992) Biochemistry of nitric oxide and its redox-activated forms. Science, 258 (5090), 1898-902.
70. Loscalzo, J. and Welch, G. (1995) Nitric oxide and its role in the cardiovascular system. Progress in Cardiovascular Diseases, 38 (2), 87-104.
71. Mendelsohn, M.E., O'Neill, S., George, D. et al. (1990) Inhibition of fibrinogen binding to human platelets by S-nitroso-N-acetylcysteine. The Journal of Biological Chemistry, 265 (31), 19028-34.
72. Michelson, A.D., Benoit, S.E., Furman, M.I. et al. (1996) Effects of nitric oxide/EDRF on platelet surface glycoproteins. American Journal of Physiology: Heart and Circulatory Physiology, 270 (5Pt 2), H1640-48.
73. Kubes, P., Suzuki, M., and Granger, D.N. (1991) Nitric oxide: an endogenous modulator of leukocyte adhesion. Proceedings of the National Academy of Sciences of the United States of America, 88 (11), 4651-55.
74. De Caterina, R., Libby, P., Peng, H.B. et al. (1995) Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proin-flammatory cytokines. The Journal of Clinical Investigation, 96 (1), 60-68.
75. Marks, D.S., Vita, J.A., Folts, J.D. et al. (1995) Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide. The Journal of Clinical Investigation, 96 (6), 2630-38.
76. Garg, U.C. and Hassid, A. (1989) Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. The Journal of Clinical Investigation, 83 (5), 1774-77.
77. Levin, E.R. (1996) Endothelins as cardiovascular peptides. American Journal of Nephrology, 16 (3), 246-51.
78. Simonson, M.S. and Dunn, M.J. (1990) Cellular signaling by peptides of the endothelin gene family. The FASEB Journal, 4 (12), 2989-3000.
79. Lopez, J.A., Armstrong, M.L., Piegors, D.J. et al. (1990) Vascular responses to endothelin-1 in atherosclerotic primates. Arteriosclerosis, 10 (6), 1113-18.
80. Warkentin, T.E., Aird, W.C., and Rand, J.H. (2003) Platelet-endothelial interactions: sepsis, HIT, and antiphospholipid syndrome. Hematology American Society of Hematology: Education Program, 497-519.
81. Siegel-Axel, D.I. and Gawaz, M. (2007) Platelets and endothelial cells. Seminars in Thrombosis and Hemostasis, 33 (2), 128-35.
82. Lindemann, S., Tolley, N.D., Dixon, D.A. et al. (2001) Activated platelets mediate inflammatory signaling by regulated interleukin 1beta synthesis. The Journal of Cell Biology, 154 (3), 485-90.
83. May, A.E., Kalsch, T., Massberg, S. et al. (2002) Engagement of glycoprotein IIb/IIIa (al-pha(IIb)beta3) on platelets upregulates CD40L and triggers CD40L-dependent matrix degradation by endothelial cells. Circulation, 106 (16), 2111-17.
84. Slupsky, J.R., Kalbas, M., Willuweit, A. et al. (1998) Activated platelets induce tissue factor expression on human umbilical vein endothelial cells by ligation of CD40. Thrombosis and Haemostasis, 80 (6), 1008-14.
85. Gawaz, M., Neumann, F.J., Dickfeld, T. et al. (1998) Activated platelets induce monocyte chemo-tactic protein-1 secretion and surface expression of intercellular adhesion molecule-1 on endothelial cells. Circulation, 98 (12), 1164-71.
86. Inwald, D.P., McDowall, A., Peters, M.J. et al. (2003) CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circulation Research, 92 (9), 1041-48.
87. Gawaz, M., Langer, H., and May, A.E. (2005) Platelets in inflammation and atherogenesis. The Journal of Clinical Investigation, 115 (12), 3378-84.
88. Damas, J.K., Otterdal, K., Yndestad, A. et al. (2004) Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation, 110 (8), 999-1005.
89. Gawaz, M. (2004) Role of platelets in coro nary thrombosis and reperfusion of ischemic myocardium. Cardiovascular Research, 61 (3), 498-511.
90. Frenette, P.S., Moyna, C., Hartwell, D.W. et al. (1998) Platelet-endothelial interactions in inflamed mesenteric venules. Blood, 91 (4), 1318-24.
91. Massberg, S., Enders, G., Matos, F.C. et al. (1999) Fibrinogen deposition at the postischemic vessel wall promotes platelet adhesion during ischemia-reperfusion in vivo. Blood, 94 (11), 3829-38.
92. Ay, C., Simanek, R., Vormittag, R. et al. (2008) High plasma levels of soluble P-selectin are predictive of venous thromboembolism in cancer patients: results from the Vienna Cancer and Thrombosis Study (CATS). Blood, 112 (7), 2703-8.
93. Jilma, B., Kovar, F.M., Hron, G. et al. (2006) Homozygosity in the single nucleotide polymorphism Ser128Arg in the E-selectin gene associated with recurrent venous thromboembolism. Archives of Internal Medicine, 166 (15), 1655-59.
94. Bonderman, D., Wilkens, H., Wakounig, S. et al. (2009) Risk factors for chronic thromboembolic pulmonary hypertension. The European Respiratory Journa, 33 (2), 325-31.
95. Adlbrecht, C., Bonderman, D., Plass, C. et al. (2006) Thrombus bound endothelin and leukocytes extracted by thrombectomy in acute myocardial infarction correlate with ST-segment resolution. Circulation, 114 (Suppl II), II-458.
96. Mackman, N. (2009) On the trail of microparticles. Circ Res. Circ Res, 104 (8), 925-7.